These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36803994)

  • 1. Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist.
    Su Z; Zhang Y; Cao J; Sun Y; Cai Y; Zhang B; He L; Zhang Z; Xie J; Meng Q; Luo L; Li F; Li J; Zhang J; Chen X; Hong A
    J Nanobiotechnology; 2023 Feb; 21(1):55. PubMed ID: 36803994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist.
    Su Z; Zhang Y; Cao J; Sun Y; Cai Y; Zhang B; He L; Zhang Z; Xie J; Meng Q; Luo L; Li F; Li J; Zhang J; Chen X; Hong A
    J Nanobiotechnology; 2024 Feb; 22(1):70. PubMed ID: 38369474
    [No Abstract]   [Full Text] [Related]  

  • 4. A cyclic peptide retards the proliferation of DU145 prostate cancer cells in vitro and in vivo through inhibition of FGFR2.
    Zhang Y; Ouyang M; Wang H; Zhang B; Guang W; Liu R; Li X; Shih TC; Li Z; Cao J; Meng Q; Su Z; Ye J; Liu F; Hong A; Chen X
    MedComm (2020); 2020 Dec; 1(3):362-375. PubMed ID: 34766128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor-based signaling through synthetic heparan sulfate blocks copolymers studied using high cell density three-dimensional cell printing.
    Sterner E; Masuko S; Li G; Li L; Green DE; Otto NJ; Xu Y; DeAngelis PL; Liu J; Dordick JS; Linhardt RJ
    J Biol Chem; 2014 Apr; 289(14):9754-65. PubMed ID: 24563485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
    Kwak Y; Cho H; Hur W; Sim T
    Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation.
    Rosini P; Bonaccorsi L; Baldi E; Chiasserini C; Forti G; De Chiara G; Lucibello M; Mongiat M; Iozzo RV; Garaci E; Cozzolino F; Torcia MG
    Prostate; 2002 Dec; 53(4):310-21. PubMed ID: 12430142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-acne agents attenuate FGFR2 signal transduction in acne.
    Melnik BC; Schmitz G; Zouboulis CC
    J Invest Dermatol; 2009 Aug; 129(8):1868-77. PubMed ID: 19225542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and comparison of the efficacy and safety of cross-linked and non-cross-linked hyaluronic acid in combination with botulinum toxin type A in the treatment of atrophic acne scars: A double-blind randomized clinical trial.
    Behrangi E; Dehghani A; Sheikhzadeh F; Goodarzi A; Roohaninasab M
    Skin Res Technol; 2024 Jan; 30(1):e13541. PubMed ID: 38174839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR2 signaling and the pathogenesis of acne.
    Melnik B; Schmitz G
    J Dtsch Dermatol Ges; 2008 Sep; 6(9):721-8. PubMed ID: 19000061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of Propionibacterium acnes Infection and the Associated Inflammatory Response by the Antimicrobial Peptide P5 in Mice.
    Ryu S; Han HM; Song PI; Armstrong CA; Park Y
    PLoS One; 2015; 10(7):e0132619. PubMed ID: 26197393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
    Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
    Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of FGF2 to FGFR2 in an autocrine mode in trophectoderm cells is indispensable for mouse blastocyst formation through PKC-p38 pathway.
    Yang J; Zhang D; Yu Y; Zhang RJ; Hu XL; Huang HF; Lu YC
    Cell Cycle; 2015; 14(20):3318-30. PubMed ID: 26378412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
    Khandelwal AR; Kent B; Hillary S; Alam MM; Ma X; Gu X; DiGiovanni J; Nathan CO
    Mol Carcinog; 2019 Oct; 58(10):1715-1725. PubMed ID: 31254372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.
    Ware KE; Marshall ME; Heasley LR; Marek L; Hinz TK; Hercule P; Helfrich BA; Doebele RC; Heasley LE
    PLoS One; 2010 Nov; 5(11):e14117. PubMed ID: 21152424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligodendrocyte-specific deletion of FGFR2 ameliorates MOG
    Kamali S; Rajendran R; Stadelmann C; Karnati S; Rajendran V; Giraldo-Velasquez M; Berghoff M
    Brain Pathol; 2021 Mar; 31(2):297-311. PubMed ID: 33103299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
    Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
    Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of FGF2/FGFR2 partially overcomes bone marrow mesenchymal stromal cells mediated progression of T-cell acute lymphoblastic leukaemia.
    Tian C; Li Y; Wang L; Si J; Zheng Y; Kang J; Wang Y; You MJ; Zheng G
    Cell Death Dis; 2022 Nov; 13(11):922. PubMed ID: 36333298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
    Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
    Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.
    Wangtrakuldee P; Adeniji AO; Zang T; Duan L; Khatri B; Twenter BM; Estrada MA; Higgins TF; Winkler JD; Penning TM
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105283. PubMed ID: 30641225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.